# Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Canonical URL: https://biopharmsignal.com/news/GANX/gain-therapeutics-to-attend-the-2025-maxim-growth-summit-2aba082f
Ticker: GANX
Company: Gain Therapeutics
Source: Gain Therapeutics
Published: 2025-10-16 11:00 EST
## Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

## Article Body
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.

Gene Mack, President and CEO of Gain, will be participating in a live discussion, “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories”, on October 22nd. The panel will include discussion about innovative approaches for a range of neurogenerative diseases that are in active clinical trials,

If you are interested in meeting with Gain management, please contact your Maxim sales representative to schedule.

About the Maxim Growth Summit

This event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Keynote speakers are to include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit .

About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors: Gain Therapeutics, Inc. Apaar Jammu Manager, Investor Relations and Public Relations ajammu@gaintherapeutics.com

LifeSci Advisors LLC Chuck Padala Managing Director chuck@lifesciadvisors.com

Media: Russo Partners LLC Nic Johnson and Elio Ambrosio nic.johnson@russopartnersllc.com elio.ambrosio@russopartnersllc.com (760) 846-9256
## Recent Company News
- 2026-07-16 11:00 EST — [Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-ceo-gene-mack-issues-letter-to-shareholders-and-provides-opera-8b796693) — Source: Gain Therapeutics
- 2026-06-29 20:05 EST — [Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease](https://biopharmsignal.com/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-11cfdeaf) — Source: Gain Therapeutics
- 2026-06-10 11:00 EST — [Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit](https://biopharmsignal.com/news/GANX/gain-therapeutics-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-exp-b322982c) — Source: Gain Therapeutics
- 2026-05-26 12:00 EST — [Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026](https://biopharmsignal.com/news/GANX/gain-therapeutics-presents-positive-interim-data-from-phase-1b-clinical-study-of-7715a5b9) — Source: Gain Therapeutics
- 2026-05-11 11:00 EST — [Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update](https://biopharmsignal.com/news/GANX/gain-therapeutics-reports-financial-results-for-first-quarter-2026-and-provides--070df9ff) — Source: Gain Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)